ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Letrozole

Also written as “letrozole”, “Letrozole Tablets 2.5 mg” and “Arm C: Gedatolisib + Palbociclib + Letrozole”.

Its studies are mostly in Breast Neoplasms · Neoplasms · Polycystic Ovary Syndrome · Endometrial Neoplasms · Infertility, led by 7 companies.

Drug pageLetrozole: every studyMany companies study it; this page follows only the 38 they lead. All 340 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 10, 200138 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis280 open or runningphase 4since Apr 10, 2001Apr 10, 2001none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Jun 13, 2011Jun 13, 2011none ahead
Egymedicalpediaits history only21 open or runningphase 1since Apr 9, 2024Apr 9, 2024none ahead
Hikma Pharmaceuticalsits history only20 open or runningphase 1since Jun 3, 2011Jun 3, 2011none ahead
Viatrisits history only20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Rovi Pharmaceuticals Laboratoriesits history only10 open or runningphase 1since Jan 8, 2018Jan 8, 2018none ahead
Sun Pharmaceutical Industriesits history only10 open or runningphase 3since Jan 24, 2008Jan 24, 2008none ahead

Also a collaborator on its studies: Gilead Sciences, Pfizer and Hoffmann-La Roche.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Apr 10, 2001.

  1. Sep 13, 2005Phase 4 study in Breast NeoplasmsNCT00171847 · 93 enrolled · Germany
  2. Sep 13, 2005Phase 2 study in Endometrial NeoplasmsNCT00171808 · 26 enrolled · Germany
  3. Oct 9, 20053 phase 4 studies in Breast NeoplasmsNCT00237224, NCT00237133, NCT00241046
  4. Oct 9, 20053 phase 2 studiesNCT00237211, NCT00237198, NCT00240942
  5. Nov 1, 20052 phase 2 studies in Breast NeoplasmsNCT00247663, NCT00247650
  6. Nov 2, 2005Phase 3 study in Breast NeoplasmsNCT00248170 · 4,172 enrolled · United States, Australia, Austria and more
  7. May 23, 20065 phase 3 studiesNCT00329940, NCT00330317, NCT00333047 and 2 more
  8. Jun 1, 2006Phase 2 study in RecurrenceNCT00333086 · 36 enrolled · Germany
  9. Sep 24, 2007Phase 3 study in Breast NeoplasmsNCT00535418 · 35 enrolled
  10. May 29, 2008Phase 4 study in Breast NeoplasmsNCT00688909 · 261 enrolled · United States
  11. Oct 28, 2010Phase 2 study in Breast NeoplasmsNCT01231659 · 72 enrolled · Israel
  12. Oct 1, 2012Phase 2 study in Breast NeoplasmsNCT01698918 · 202 enrolled · United States, Argentina, Brazil and more
  13. Feb 15, 2017Phase 2 study in Breast NeoplasmsNCT03056755 · 383 enrolled · United States, Argentina, Belgium and more
  14. Jan 29, 2018Phase 3 study in Breast NeoplasmsNCT03439046 · 287 enrolled · Italy

TargetBeta

CYP19A1 →read by rule
“Cytochrome P450 19A1 inhibitor”ChEMBL 37, by rule

Studies

All 28 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03439046Breast Neoplasms · Italy3TerminatedDec 11, 2023287
NCT03056755Breast Neoplasms · United States, Argentina, Belgium and more2CompletedJun 14, 2021383
NCT01698918Breast Neoplasms · United States, Argentina, Brazil and more2CompletedDec 17, 2015202
NCT01231659Breast Neoplasms · Israel2CompletedNov 20, 201272
NCT00688909Breast Neoplasms · United States4CompletedJun 2009261
NCT00535418Breast Neoplasms3CompletedJul 200235
NCT00333086Recurrence · Germany2CompletedJun 200636
NCT00333047Breast Neoplasms · Germany3Completed24
NCT00332852Breast Neoplasms · Germany3CompletedJul 2010655
NCT00332709Osteoporosis · Germany3CompletedAug 201083
NCT00330317Breast Neoplasms · United Kingdom3CompletedMar 2010300
NCT00329940Breast Neoplasms · France3CompletedJan 2008200
NCT00248170Breast Neoplasms · United States, Australia, Austria and more3CompletedSep 20144,172
NCT00247663Breast Neoplasms · Japan2CompletedDec 200517
NCT00247650Breast Neoplasms · Canada2CompletedMar 2007190
NCT00241046Breast Neoplasms4TerminatedMar 200513
NCT00240942Endometriosis2CompletedJun 200640
NCT00237224Breast Neoplasms · Mexico4CompletedFeb 200740
NCT00237211Breast Neoplasms · Japan2CompletedOct 200631
NCT00237198Breast Neoplasms · Japan2CompletedJul 200647
NCT00237133Breast Neoplasms · Brazil4CompletedJan 2009112
NCT00171847Breast Neoplasms · Germany4TerminatedOct 200893
NCT00171808Endometrial Neoplasms · Germany2CompletedMay 201026
NCT00171704Breast Neoplasms · Denmark, United Kingdom3CompletedMar 2011263
NCT00171340Bone Diseases, Metabolic · Argentina, Australia, Belgium and more3CompletedFeb 20101,065
NCT00171314Breast Neoplasms · Argentina, Belgium, France and more3CompletedNov 2010527
NCT00050011Breast Neoplasms · United States, Puerto Rico3CompletedJan 2009602
NCT00014638Breast Neoplasms · United States4CompletedMar 2002

How it is read

Names in the registry

  • “Letrozole”, 40 entries
  • “letrozole”, 6 entries
  • “Letrozole Tablets 2.5 mg”, 2 entries
  • “Arm C: Gedatolisib + Palbociclib + Letrozole”, 1 entry
  • “PF-07104091 + PF-07220060 + letrozole dose expansion”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.